- Home
- SKYE vs ACNB Comparison
SKYE vs ACNB Comparison
Compare SKYE & ACNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- ACNB
- Stock Information
- Founded
- SKYE 2012
- ACNB 1857
- Country
- SKYE United States
- ACNB United States
- Employees
- SKYE N/A
- ACNB N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- ACNB Major Banks
- Sector
- SKYE Health Care
- ACNB Finance
- Exchange
- SKYE Nasdaq
- ACNB Nasdaq
- Market Cap
- SKYE 108.3M
- ACNB 372.5M
- IPO Year
- SKYE N/A
- ACNB N/A
- Fundamental
- Price
- SKYE $4.94
- ACNB $43.28
- Analyst Decision
- SKYE Buy
- ACNB Buy
- Analyst Count
- SKYE 6
- ACNB 2
- Target Price
- SKYE $18.67
- ACNB $37.00
- AVG Volume (30 Days)
- SKYE 308.0K
- ACNB 15.0K
- Earning Date
- SKYE 11-09-2024
- ACNB 10-29-2024
- Dividend Yield
- SKYE N/A
- ACNB 3.03%
- EPS Growth
- SKYE N/A
- ACNB N/A
- EPS
- SKYE N/A
- ACNB 3.66
- Revenue
- SKYE N/A
- ACNB $106,710,000.00
- Revenue This Year
- SKYE N/A
- ACNB N/A
- Revenue Next Year
- SKYE N/A
- ACNB $21.19
- P/E Ratio
- SKYE N/A
- ACNB $11.54
- Revenue Growth
- SKYE N/A
- ACNB N/A
- 52 Week Low
- SKYE $1.44
- ACNB $30.24
- 52 Week High
- SKYE $19.41
- ACNB $48.55
- Technical
- Relative Strength Index (RSI)
- SKYE 58.26
- ACNB 54.90
- Support Level
- SKYE $4.01
- ACNB $42.24
- Resistance Level
- SKYE $5.48
- ACNB $44.45
- Average True Range (ATR)
- SKYE 0.46
- ACNB 1.03
- MACD
- SKYE 0.19
- ACNB -0.00
- Stochastic Oscillator
- SKYE 73.79
- ACNB 67.64
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About ACNB ACNB Corporation
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Bank which generates the majority of the revenue provides banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.